ARC has in-licensed promising product candidates that have early, in vitro proof-of-principle data in markets with unmet needs and the Company is focused on the preclinical and clinical development of the lead product candidate, ARCADÔ Instillate.

The Company has completed the formulation, pilot-scale manufacturing, preclinical efficacy studies and pilot safety studies for ARCADÔ Instillate, .  ARC intends to complete the formal preclinical and pilot human studies for ARCADÔ Instillate.